Baidu
map

Oncol Rep: PARP1-siRNA能够抑制人类前列腺癌细胞的生长和恶化

2018-02-21 AlexYang MedSci原创

Poly聚合酶(PARP)抑制剂,比如奥拉帕尼或者rucaparib,在BRCA1/2缺陷型肿瘤中展现出了治疗活性。然而,虽然PARP抑制剂(PARPi)主要调控PARP的激活而不是表达,是否PARP特异性针对的小干扰RNA(siRNA)与PARRPi具有与相同的功能仍旧未知。最近,有研究人员阐释了不考虑BRCA1/2的变异,PARP-1能够减少前列腺癌(PCa)细胞的恶化。PARP1的沉默能够显

Poly聚合酶(PARP)抑制剂,比如奥拉帕尼或者rucaparib,在BRCA1/2缺陷型肿瘤中展现出了治疗活性。然而,虽然PARP抑制剂(PARPi)主要调控PARP的激活而不是表达,是否PARP特异性针对的小干扰RNA(siRNA)与PARRPi具有与相同的功能仍旧未知。

最近,有研究人员阐释了不考虑BRCA1/2的变异,PARP-1能够减少前列腺癌(PCa)细胞的恶化。PARP1的沉默能够显著的抑制PC3细胞的迁移和入侵。另外,PARP1-siRNA同样能够抑制PC3和Du145细胞的增殖。在多烯紫杉醇诱导的细胞凋亡之后,PARP1-siRNA能够抑制PC3细胞异种种植肿瘤的大小并且产生一种更加常规的形态。在体内和体外试验中,PARP-1沉默能够显著地下调波形蛋白的表达和上调E-钙粘蛋白的表达,两者均是上皮-间质转化(EMT)的标记。PI3K抑制剂能够使得PARPi的作用更加明显。显著的是,PARP1-siRNA能够抑制EGFR和p-GSK3β 在前列腺癌细胞中的表达,这与PARPi的作用不同。

最后,研究人员指出,他们的结果表明了PARP1-siRNA能够抑制PCa细胞的生长和入侵能力,因此表明了PARP1-siRNA与PARPi的作用是不同的,这也许为PCa的治疗提供了一个潜在的治疗方法。

原始出处:

Lai Y, Kong Z, Zeng T et al. PARP1-siRNA suppresses human prostate cancer cell growth and progression. Oncol Rep. 26 Jan 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
    2018-11-09 minlingfeng
  2. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
    2018-02-25 梦想起航ing

    学习了.很棒.谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
    2018-02-23 yxch36
  5. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1865344, encodeId=0b8d1865344d6, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b63894, createdName=minlingfeng, createdTime=Fri Nov 09 08:01:00 CST 2018, time=2018-11-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1674304, encodeId=764916e430451, content=<a href='/topic/show?id=466013e58de' target=_blank style='color:#2F92EE;'>#PARP1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=123, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13758, encryptionId=466013e58de, topicName=PARP1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d93c26968892, createdName=bnjfx@135.com, createdTime=Fri Jun 01 10:01:00 CST 2018, time=2018-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=290773, encodeId=096c290e731f, content=学习了.很棒.谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=113, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/11/17/cfa76f1048392033b44c71e9bcb628d9.jpg, createdBy=096c2156900, createdName=梦想起航ing, createdTime=Sun Feb 25 09:48:09 CST 2018, time=2018-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1252472, encodeId=71b112524e209, content=<a href='/topic/show?id=3efee1519b2' target=_blank style='color:#2F92EE;'>#癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71519, encryptionId=3efee1519b2, topicName=癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4cea26, createdName=yxch36, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1548195, encodeId=8f4915481955e, content=<a href='/topic/show?id=c87e16332da' target=_blank style='color:#2F92EE;'>#siRNA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16332, encryptionId=c87e16332da, topicName=siRNA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=271114029857, createdName=12498ebem23暂无昵称, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620230, encodeId=daa916202309f, content=<a href='/topic/show?id=c62132549a5' target=_blank style='color:#2F92EE;'>#前列腺癌细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32549, encryptionId=c62132549a5, topicName=前列腺癌细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e09820091072, createdName=lifestar, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1621322, encodeId=4ec816213227e, content=<a href='/topic/show?id=49b313e56ad' target=_blank style='color:#2F92EE;'>#PARP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13756, encryptionId=49b313e56ad, topicName=PARP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fd4d20248280, createdName=lishiwen, createdTime=Fri Feb 23 10:01:00 CST 2018, time=2018-02-23, status=1, ipAttribution=)]
    2018-02-23 lishiwen

相关资讯

ASCO-GU 2018:寡转移性前列腺癌的临床处理

2018年ASCO GU研讨会于当地时间2月8日在旧金山拉开帷幕,吸引了超过4300名来自世界各地的泌尿生殖肿瘤专家和基础研究学者参与。论坛首日的内容是关于前列腺癌的临床和基础研究进展,寡转移性前列腺癌(Oligometastatic Prostate Cancer)的诊疗是本次论坛的讨论热点之一。

Prostate:血浆中循环microRNAs是前列腺癌早期检测的潜在生物标记

microRNAs(miRNAs)与前列腺癌(PC)风险相关,然而,它们作为一个PC筛选生物标记的作用还未被鉴定。最近,有研究人员探究了是否在那些经历了前列腺癌针刺活检的男性中,血浆中的循环miRNAs能够成为PC早期检测潜在的生物标记。研究包括了134名男性,年龄在46-86岁之间,其中66名男性具有PC诊断结果(案例),8名男性没有PC诊断结果但是具有不典型病变,60名男性没有PC诊断结果(对

Sci Rep:Hsp抑制剂对纤连蛋白转运的异常调节能够抑制前列腺癌细胞的入侵

分子伴侣Hsp90在前列腺癌(PCa)中过表达并且与多种癌基因蛋白的折叠、稳定化和成熟相关,这些均与PCa的恶化相关。与第一代Hsp90抑制剂相比,比如17-allylamino-demeth oxygeldanamycin(17-AGG)在临床治疗中效果较差,而第二代抑制剂AUY922具有更好的溶解性和治疗效果。最近,有研究人员对病人来源的PCa外植体的转录组和蛋白组分析鉴定了细胞骨架组织在AU

Brit J Cancer:多烯紫杉醇结合Aneustat治疗能够强烈的抑制晚期前列腺癌的转移

多烯紫杉醇是治疗晚期前列腺癌(PCa)的首选药物,并且只有较低水平的治疗效果。之前研究人员表明,利用LTL-313H肾包膜来源的转移性PCa异种种植模型,且利用一种多烯紫杉醇结合Aneustat(OMN54),能够明显的增强肿瘤生长抑制作用。最近,有研究人员调查了多烯紫杉醇+Aneustat组合疗法对转移的影响。研究人员发现,多烯紫杉醇+Aneustat组合疗法能够显著的抑制C4-2细胞迁移和LT

J Clin Oncol:转移性激素敏感前列腺癌化学激素治疗分析

将多烯紫杉醇加入到雄激素阻断治疗(ADT)中能够显著的增加一些患有转移激素敏感性前列腺癌患者的寿命。最近,有研究人员呈现了CHAARTED(前列腺癌广泛性疾病的化学激素治疗VS雄激素阻断随机试验)试验结果,并且具有更加成熟的跟踪调查且关注肿瘤体积。研究包括了790名患有转移性激素敏感前列腺癌的患者,并且被随机平均分配到接受ADT结合多烯紫杉醇75mg/m2或者只接受ADT治疗的两个小组中。研究发现

Baidu
map
Baidu
map
Baidu
map